A Chinese firm racing to develop a coronavirus vaccine has received additional funding from investors. Beijing-based Sinovac Biotech Ltd. obtained $15m from Advantech Capital and Vivo Capital, raising $7.5m from each of the investors. The new funds will be used to accelerate Sinovac’s candidate, CoronaVac, into Phase II development.
In April, the company announced a Phase I study of the inactivated virus product and is planning to start the Phase II program to test immune response and safety in a larger population in May
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?